哈奇美德正在推进癌症药物管道,主要候选药物HMPL-A251将于2025年底进入试验. Hutchmed advances cancer drug pipeline, with key candidate HMPL-A251 entering trials late 2025.

HUCHMED于2025年10月31日宣布其肿瘤管道的进展,强调其下一代ATTC平台,该平台使用抗体定向发送小分子抑制剂,用双重机制治疗癌症。 HUTCHMED announced on October 31, 2025, progress in its oncology pipeline, highlighting its next-generation ATTC platform, which uses antibody-targeted delivery of small-molecule inhibitors to attack cancer with dual mechanisms. 其主要候选人HMPL-A251以HER2-阳性癌症和HER2-low癌症为对象,对PAM路径进行了改造,结果显示临床前期效果很强,包括提高了现有治疗的功效和安全性。 Its lead candidate, HMPL-A251, targeting HER2-positive and HER2-low cancers with PAM pathway alterations, showed strong preclinical results, including improved efficacy and safety over existing treatments. 该公司计划在2025年底开始HMPL-A251的临床试验。 The company plans to begin clinical trials for HMPL-A251 in late 2025. 其他最新资料包括:肾癌Fruquintinib-sintilimab第3阶段的正面数据,以及目前对胰腺癌的surufatinib和肺癌的fanregratinib进行的晚期试验。 Additional updates include positive Phase III data for fruquintinib-sintilimab in kidney cancer and ongoing late-stage trials for surufatinib in pancreatic cancer and fanregratinib in bile duct cancer.